22.76
Structure Therapeutics Inc Adr stock is traded at $22.76, with a volume of 697.04K.
It is down -4.02% in the last 24 hours and down -19.59% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
See More
Previous Close:
$23.75
Open:
$23.77
24h Volume:
697.04K
Relative Volume:
0.83
Market Cap:
$1.29B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-10.25
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
+8.39%
1M Performance:
-19.59%
6M Performance:
-40.28%
1Y Performance:
-44.73%
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GPCR
Structure Therapeutics Inc Adr
|
22.83 | 1.29B | 0 | -100.44M | -105.32M | -2.22 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
488.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
688.49 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.34 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
112.79 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-28-25 | Initiated | William Blair | Outperform |
Jan-08-25 | Initiated | Stifel | Buy |
Dec-04-24 | Initiated | H.C. Wainwright | Buy |
Sep-23-24 | Initiated | Morgan Stanley | Overweight |
May-21-24 | Initiated | JP Morgan | Overweight |
Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
Jul-27-23 | Initiated | Piper Sandler | Overweight |
May-25-23 | Resumed | Jefferies | Buy |
Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
Feb-28-23 | Initiated | Guggenheim | Buy |
Feb-28-23 | Initiated | Jefferies | Buy |
Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Leerink cuts Structure Therapeutics target to $60, keeps outperform - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at William Blair - Defense World
Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at William Blair - MarketBeat
Structure Therapeutics Advances in Obesity Treatment Pipeline - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 8% on Earnings Beat - MarketBeat
Structure Therapeutics, Inc.: Promising Outlook with Aleniglipron in Obesity Treatment and Strategic Advancements Justify Buy Rating - TipRanks
Promising Potential of Structure Therapeutics’ Aleniglipron: A Compelling Buy Recommendation - TipRanks
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Average Price Target from Brokerages - MarketBeat
Buy Rating for Structure Therapeutics: Promising Phase 2b Trials and Strong Financial Position - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week LowTime to Sell? - MarketBeat
Structure Therapeutics reports Q4 net loss $36.5M vs. net loss $24.5M last year - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.4%Time to Sell? - MarketBeat
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights - The Manila Times
Handelsbanken Fonder AB Acquires Shares of 165,000 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
GPCR stock touches 52-week low at $20.11 amid market challenges By Investing.com - Investing.com South Africa
GPCR stock touches 52-week low at $20.11 amid market challenges - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.2%Here's Why - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Sees Large Decline in Short Interest - MarketBeat
GPCR Stock Hits 52-Week Low at $23.48 Amid Market Challenges - Investing.com Canada
Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Here’s What Happened - Defense World
Why Structure Therapeutics Stock Was Stumbling This Week - The Globe and Mail
abrdn plc Sells 45,695 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Financial Fitness Check: Examining Structure Therapeutics Inc ADR (GPCR)’s Key Ratios - The Dwinnex
Spire Wealth Management Acquires Shares of 8,949 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.7%Should You Sell? - MarketBeat
HSBC Securities Downgrades Morgan Stanley (MS) to a Hold from a Buy - Knox Daily
JD.com Inc ADR (JD) receives an Outperform rating from Bernstein - Knox Daily
Ratio Examination: Bausch Health Companies Inc (BHC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - MarketBeat
Understanding the Recent Fluctuations of Structure Therapeutics Inc ADR’s (GPCR) Stock - The News Heater
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - MarketBeat
CCG Wealth Management LLC Makes New $4.07 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World
GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 - Grand View Research
Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8% - Defense World
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 8.3%Still a Buy? - MarketBeat
Structure Therapeutics Lines Up Triple Conference Appearances: What's Next for GPCR? - StockTitan
Fidelity Electric Vehicles and Future Transportation ETF (BATS:FDRV) Shares Up 0.5% – Still a Buy? - Defense World
Liberty TripAdvisor (NASDAQ:LTRPA) Now Covered by Analysts at StockNews.com - Defense World
ImmuPharma (LON:IMM) Trading 13.6% Higher – Here’s What Happened - Defense World
JPMorgan Chase & Co. Has $1.31 Million Stock Holdings in iShares International Treasury Bond ETF (NASDAQ:IGOV) - Defense World
JPMorgan Chase & Co. Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Air T (NASDAQ:AIRT) Shares Cross Below 200-Day Moving Average – What’s Next? - Defense World
JPMorgan Chase & Co. Acquires 25,500 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):